Business
Theralase(R) Granted Canadian Anti-Cancer Patent
Theralase Granted Canadian Patent for Metal-Glycoprotein Complexes Used to Hunt Cancer Cells...
About this update from Theralase Technologies Inc.
[{"type":"text","content":"Theralase(R) Granted Canadian Anti-Cancer PatentTheralase Granted Canadian Patent for Metal-Glycoprotein Complexes Used to Hunt Cancer Cells and When Laser Light Activated Destroy ThemTORONTO, ON / ACCESSWIRE / November 15, 2018 / Theralase Technologies Inc. (\"Theralase®\" or the \"Company\") (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (\"PDCs\") and their associated drug formulations, used to safely and effectively destroy various cancers is pleased to announce that it has been granted a Canadian patent protecting its unique metal-glycoprotein complexes used to hunt cancer cells and when laser light activated destroy them.The Canadian patent entitled, \"Metal-Glycoprotein Complexes And Their Use As Chemotherapeutic Compounds\" is critical in protecting Theralase's systemic and targeted anti-cancer therapies to allow PDCs and their associated drug formulations to be systemically injected to hunt and destroy cancer cells for various cancer conditions.Arkady Mandel, M.D., Ph.D., D.Sc., Interim Chief Executive Officer and Chief Scientific Officer, Theralase® stated that, \"The granting of this key patent is timely as we embark on the commencement of a Phase II Non-Muscle Invasive Bladder Cancer (\"NMIBC\") clinical study and complete the preclinical research for two additional cancer indications; specifically: GlioBlastoma Multiforme (\"GBM\"), a deadly form of brain cancer and Non-Small Cell Lung Cancer (\"NSCLC\"). This patent validates the proprietary position of the Company's anti-cancer technology for the Canadian healthcare market, demonstrating Theralase's ongoing commitment to the development of a comprehensive intellectual property portfolio, to protect the Company's future interests, as well as to be attractive to an early stage partner, when the time is right. The latest patent contains significant potential to advance the Company's anti-cancer Photo Dynamic Therapy (\"PDT\") and its associated anti-cancer immune response to additional cancer targets; including: GBM and NSCLC. I am pleased that the patent that protects our advanced PDC formulations and the technology behind it, is in full force in Canada.\"About the PatentCompositions of the invention include glycoproteins, such as transferrin, and meta...